



# Stuart Allan Ross MB CHB, FRACP, FRCP(c)

Calgary 102-5940 MacLeod Trail SW, Calgary, Alberta, T2H 2G4, Canada

Tel(403) 288-3224

## CURRICULUM VITAE

### Education, Certification & Licenses

1980	FRCP(C)	Fellow Royal College of Physicians and Surgeons Canada
1976	LMCC	
1974	FRACP	Fellow Royal Australasian College of Physicians
1971	MRACP	Member Royal Australasian College of Physicians
1965	M.B. Ch.B - Medicine	Otago University, Dunedin, New Zealand

### Professional Activities

2009 - present	Associate Endocrinologist	LMC Diabetes & Endocrinology.
1994 - present	Director	Calgary Metabolic Education and Research Centre, Calgary, Alberta
1991- present	Director	Foundation Board Mt. Royal College; Advisor, Treaty Seven Tribal Council, Southern Alberta
1985 - present	Clinical Professor of Medicine	University of Calgary, Calgary, Alberta
1983 - present	Director	Kahanoff Foundation
1975 - present	Faculty of Medicine	University of Calgary, Calgary, Alberta
1984 - 1996	Director, Southern Alberta Study of Diabetic Retinopathy	University of Calgary, Calgary, Alberta
1994 - 1997	Federal Task Force Committee	"Towards 2000"
1975-1991	Director	Diabetes Education and Treatment Centre Foothills Provincial Hospital
1972 - 1975	Diabetes Research Fellow	McGill University, Montreal, Quebec
1970-1972	Bank of New Zealand Research Fellow in Carbohydrate Metabolism	Auckland, New Zealand, Dr. H. K. Ibbertson (Professor of Endocrinology)
1968-1970	Senior Resident in Endocrinology	Auckland Hospital Board
1966-1967	Rotating Internship and Residency	Auckland Hospital Board

### Achievements, Associations & Specialties\*

Textbooks	Stuart Ross, Roger Gadsby: Diabetes and Related Disorders: Publisher-Mosby, 2004
	Stuart A. Ross. Commencing Insulin Therapy in the Older Patient with Type 2 Diabetes. Geriatrics and Aging, Vol 7, 1, p12-16, January 2004
	S.A. Ross; Controlling Diabetes: The need for intensive therapy-barriers in clinical management; Diabetes Research and Clinical Practice; Vol 65S S29-S34, 2004
Abstracts	<u>Ross, S.A.</u> , Fick, G.H., Guo, D.L., Effect of HbA1c on the Incidence and Rate of Progression of Diabetic Retinopathy in Native and Non-Native Canadians. Clinical and Investigative Medicine, 1995; Vol 18 (4): B45
	<u>Ross, S.A.</u> , Josefsberg, Z., Fick, G.H., Burgess, E. Comparison of the Effect of Nitrendipine and Enalapril on Microalbumin Secretion in Non-Insulin-Dependent Diabetic Subjects. Clinical and Investigative Medicine 1993; Vol 16 (4):A200
	<u>Ross, S.A.</u> , Fick,G.H. Inadequate Treatment Of High Risk Factors Responsible For Complications Of Diabetes, A30,Vol 15,4,1992
Publications	<u>Ross,S.A.</u> Education? Yes! But how should we deliver it? Canadian Journal of Diabetes Care 25:3/151 2001
	<u>Ross, S.A.</u> ,Zinman, B.,Campos,R.V., Strack, T. and the Canadian Lispro Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001;24(6):292-8
	<u>Ross SA</u> Meeting the Clinical Challenge of Diabetes and Associated Risk Factors. Perspectives in Cardiology, 1997, 13, 8, 1-2

### Clinical Trials & Research

2010-2016	J& J 3004(J&J), J&J 3012(J & J), TAK-875_306(Takeda), Defend-1(GSK), Defend-2(GSK), Eprosidale(Bellus Health), R331333-PAI-3027 (J&J), 1245.10(BI), 1218.83(BI), J & J 3008(J&J), DAPA19(AstraZeneca), 1218.83(BI), EFC11628(Sanofi-aventis), J &J3015(J&J), GBDN(Lilly), 1218.62(BI), GBCF(Lilly), BEGIN 3672(NovoNordisk), REWIND(Lilly), OpT2mise(Medtronic), 1245.36(BI), 1001(Andromeda), MB102-029(BMS), DECLARE(AstraZeneca), B1481022(Pfizer), B1481038(Pfizer), APD356-G000-401(Eisai), MK8835-002(Merck), B1481045(Pfizer), J&J 2004(Janssen Research), LX4211.309(Lexicon), etc.
2009	Exubera A217-1029/1022 (Pfizer), DIRECT (AstraZeneca), NN2211-1574 (NovoNordisk),1218.5 (BI), 1218.18 (BI), 1218.40 (BI), Navigator (Novartis), Generex, Levenir (Novartis), 1218.46 (BI), 1218.36 (BI), MB102-035 (BMS), 1218.52 (BI), etc.
2008	CLAF 237A 2327 (Novartis), Hyzaar-TS (Merck-Frosst), A0081084 (Pfizer), KRX 101-103, KRX 101-104, ADVANCE (Sanofi-aventis), IOOV (Lilly), MBBK/MBBM (Lilly), PROT202 (Phenomix 1149), TIDE (GSK), Mercury 1 (AstraZeneca), etc.
2007	BMS 057 (BMS), GWCE (Lilly), SOLVE (NovoNordisk), BI 1218.46 (BI), CL503011 (Bellus Health), BMS 029 (BMS), FUSE (Pfizer), BI 1218.40 (BI), CLAF 2308 (Novartis), etc
1994-2006	Greater than 100 clinical trials phase II through IV at the Calgary Metabolic education and research centre

\* 3 Textbook publications, 53 Abstracts and 57 Publications in total. Detailed List available upon request.